Product Detailed Description

liposomal Nicotinamide Riboside Chloride 70% — High Bioavailability NAD+ Precursor Supplement

Product Overview

Liposomal Nicotinamide Riboside Chloride 70% is a premium-grade dietary supplement ingredient delivering nicotinamide riboside chloride in an advanced liposomal delivery system. Nicotinamide riboside chloride (CAS 23111-00-4), also known as 3-carbamoyl-1-β-D-ribofuranosylpyridinium chloride, is a pyridinium salt with the molecular formula C₁₁H₁₅N₂O₅·Cl and a molecular weight of 290.7 g/mol. It occurs as a white to light brown powder that is freely soluble in water and belongs to the vitamin B3 family.

Nicotinamide riboside is a naturally occurring molecule found in all cells and a natural building block for NAD⁺ production. NAD⁺ is a coenzyme present in all living cells that is essential for cellular Energy Metabolism, mitochondrial function, and DNA repair. NAD⁺ levels decline with age, and restoring NAD⁺ has become a major focus of longevity research. NR is uniquely and orally bioavailable in mice and humans, making it one of the most promising NAD⁺ precursors for clinical applications.

Why Liposomal Technology?

Conventional NR chloride presents formulation challenges including hygroscopicity, potential degradation, and variable absorption. NR can degrade under certain conditions, particularly to nicotinamide, and is hygroscopic in nature. While NR is already orally bioavailable, optimizing its delivery can further enhance its therapeutic potential.

Liposomal encapsulation provides four critical advantages:

1. Enhanced Bioavailability and Plasma Concentration — Liposomal NR formulations have been shown to achieve 73% higher plasma concentrations compared to conventional NR formulations, and independent lab tests show that liposomal NR achieves 58% absorption compared to only 8% for non-encapsulated forms.

2. Enhanced Brain Delivery — Liposomal NR delivers nearly 3× higher brain concentration than conventional NR, supporting its potential for neuroprotective applications. A study demonstrated that liposome-based loading enhances the distribution of nicotinamide riboside chloride into the brain and its neuroprotective effect.

3. Protection from Degradation and Hygroscopicity — The phospholipid bilayer shields NR from moisture absorption, oxidative degradation, and pH-dependent breakdown, preserving its intact molecular structure until reaching optimal absorption sites.

4. Enhanced Cellular Uptake — Liposomes fuse directly with intestinal cell membranes, facilitating efficient cellular delivery via lipid-mediated pathways. Liposomal encapsulation prevents NR degradation and enhances absorption, ensuring effective delivery to cells and maximizing bioavailability.

Product Specifications

Key Features

• High Purity — Standardized to ≥70% nicotinamide riboside chloride by HPLC, ensuring consistent active content.

• Liposomal Enhancement — Phospholipid bilayer encapsulation achieves 73% higher plasma concentrations and 58% absorption compared to 8% for non-encapsulated forms, with nearly 3× higher brain concentration than conventional NR.

• Potent NAD⁺ Precursor — NR is a member of the vitamin B3 family that is converted in the body to NAD⁺, a coenzyme essential for cellular energy and mitochondrial function.

• Clinically Validated NAD⁺ Elevation — A randomized, double-blind, crossover study in 12 healthy participants demonstrated that single doses of 100 mg, 300 mg, and 1,000 mg NR increased NAD⁺ AUC by 48%, 59%, and 92% respectively. An eight-week randomized trial in 140 overweight adults showed that 100, 300, and 1,000 mg NR per day increased whole-blood NAD⁺ by 22%, 51%, and 142%.

• Excellent Safety Profile — NR is safe and well tolerated. The FDA and EFSA have approved daily doses up to 300 mg as safe, with clinical trials supporting doses up to 3,000 mg per day with appropriate safety monitoring.

• Water-Dispersible — Freely soluble in water; suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Clinical studies have evaluated NR across a range of doses. A randomized, double-blind, crossover study in 12 healthy participants used single doses of 100 mg, 300 mg, and 1,000 mg, demonstrating NAD⁺ AUC increases of 48%, 59%, and 92% respectively. An eight-week randomized trial in 140 overweight adults used 100, 300, and 1,000 mg/day, with whole-blood NAD⁺ increasing by 22%, 51%, and 142% respectively. A randomized, placebo-controlled trial in older adults with mild cognitive impairment used dose escalation to achieve and maintain a final dose of 1 g/day over 10 weeks. The NR-SAFE trial in Parkinson‘s disease patients used 1,500 mg twice daily (3,000 mg/day) for four weeks and supported extending the dose range to 3,000 mg per day with appropriate safety monitoring. For general NAD⁺ support, 100–300 mg daily is commonly used, while 500–1,000 mg daily is used in clinical research settings. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.